Spermosens Beheer

Beheer criteriumcontroles 1/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Tore Duvold

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	less than a year
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	less than a year
Gemiddelde ambtstermijn bestuur	3.3yrs

Recente managementupdates

Recent updates

CEO

Tore Duvold (56 yo)

less than a year

Tenure

Mr. Tore Duvold serves as Chief Executive Officer at Spermosens AB from May 01, 2024. He served as Chief Executive Officer at Coegin Pharma AS since September 2020 until 2023 and served as its Director sin...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Ulrik Nilsson	Part Time Chief Financial Officer	3.8yrs	SEK 1.59m	8.96% SEK 294.8k
Tore Duvold	Chief Executive Officer	less than a year	geen gegevens	geen gegevens
Maria Liljander	Chief Scientific Officer	less than a year	geen gegevens	geen gegevens

0.5yrs

Gemiddelde duur

Ervaren management: Het managementteam van SPERM wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 0.5 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Ulrik Spork	Independent Chairman of the Board	less than a year	geen gegevens	geen gegevens
Soren Frederiksen	Independent Director	4.8yrs	SEK 131.00k	0.14% SEK 4.6k
Kushagr Punyani	Director	6.8yrs	SEK 131.00k	0.58% SEK 19.0k
Ingela Soltic	Independent Director	5.8yrs	SEK 131.00k	geen gegevens
Aleksander Giwercman	Member of Advisory Board	3.3yrs	geen gegevens	geen gegevens
Trine Haugen	Member of Advisory Board	3.3yrs	geen gegevens	geen gegevens
Emir Henic	Member of Advisory Board	3.3yrs	geen gegevens	geen gegevens
Claus Andersen	Member of Advisory Board	3.3yrs	geen gegevens	geen gegevens
Christina Ostberg-Lloyd	Independent Director	2.5yrs	SEK 131.00k	geen gegevens

3.3yrs

Gemiddelde duur

48yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van SPERM wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.3 jaar).

Spermosens Beheer

Beheer criteriumcontroles 1/4

Belangrijke informatie

Recente managementupdates

Spermosens AB, Annual General Meeting, May 10, 2024

High number of new and inexperienced directors

High number of new and inexperienced directors

Recent updates

Spermosens AB Provides Update on Clinical Study Progress

Spermosens AB Announces Advancements in Second-Generation JUNO-Checked System

Spermosens AB to Report Q3, 2024 Results on Nov 28, 2024

Spermosens AB (publ) Receives Notice of Allowance for Broad US Patent Covering JUNO-Checked Technology

Spermosens AB Announces A Significant Milestone in Its Clinical Study of the Next-Generation Fertility Diagnostic Product

Spermosens AB to Report First Half, 2024 Results on Jul 12, 2024

New major risk - Shareholder dilution

Spermosens AB to Report Q1, 2024 Results on May 30, 2024

Spermosens AB, Annual General Meeting, May 10, 2024

Spermosens AB to Report Q3, 2024 Results on Mar 25, 2024

New major risk - Share price stability

Spermosens AB to Report Fiscal Year 2023 Results on Feb 09, 2024

Third quarter 2023 earnings released: kr0.085 loss per share (vs kr0.27 loss in 3Q 2022)

Spermosens AB to Report Q3, 2023 Results on Oct 13, 2023

New major risk - Share price stability

Spermosens AB to Report Q2, 2023 Results on Jul 14, 2023

First quarter 2023 earnings released: kr0.12 loss per share (vs kr0.24 loss in 1Q 2022)

Full year 2022 earnings released: kr1.10 loss per share (vs kr0.73 loss in FY 2021)

Spermosens AB has completed a Composite Units Offering in the amount of SEK 24.425427 million.

Spermosens AB to Report Fiscal Year 2022 Results on Feb 08, 2023

High number of new and inexperienced directors

Third quarter 2022 earnings released: kr0.27 loss per share (vs kr0.19 loss in 3Q 2021)

Second quarter 2022 earnings released: kr0.34 loss per share (vs kr0.25 loss in 2Q 2021)

High number of new and inexperienced directors

First quarter 2022 earnings released: kr0.24 loss per share (vs kr0.17 loss in 1Q 2021)

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

European Patent Office Grants Patent to Spermosens AB

CEO

Tenure

Leiderschapsteam

Gemiddelde duur

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd